Evidence map›Paper›PMID 40601653›Full record

ArticlePloS one2025

Tumor-associated macrophage-based predictive and prognostic model for hepatocellular carcinoma.

Changquan Shang, Tiancong He, Yi Zhang

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Changquan ShangDepartment of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center, Shanghai, China.
Tiancong HeDepartment of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center, Shanghai, China.
Yi ZhangDepartment of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID https://orcid.org/0009-0002-6353-0001

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a prevalent malignancy influenced by the interplay between the immune system and tumor progression, but the detailed biological mechanism still elusive. To address this, we integrate single-cell RNA sequencing (scRNAseq) data with bulk sequencing data to investigate the prognostic significance of tumor-associated macrophages (TAMs) signatures in HCC. Utilizing bioinformatics approaches, including differential gene expression analysis, Cox regression, and logistic regression modeling, we constructed a robust prognostic model that effectively stratifies HCC patients into distinct risk groups with significant differences in survival outcomes. Applying our model to multiple HCC cohorts, robust predictive and prognostic performances were observed. Moreover, examination of the tumor microenvironment (TME) revealed distinct patterns of immune cell infiltration between high-risk and low-risk patient groups, which may contribute to the poorer outcomes observed in high-risk patients. Finally, drug sensitivity and AutoDock simulations suggest that the signature genes we identified could be potential targets for HCC therapy. In summary, this study provides novel insights into the HCC tumor microenvironment and its interaction with TAMs, offering a prognostic model with potential for improving patient stratification and guiding the development of novel therapeutic approaches. Future research ought to concentrate on confirming our findings in larger, prospective studies and examining the functional implications of TAMs in HCC progression.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsTumor-Associated MacrophagesBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisTumor MicroenvironmentBiomarkers, Tumor

Identifiers

PMID40601653
PMCPMC12221018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.